Navigation Links
Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/12/2011

NEW YORK, Dec. 12, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that Ivan Bergstein, MD, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 10:15 a.m. ET at the Waldorf Astoria Hotel in New York City.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
4. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
5. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
6. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
7. Cell Therapeutics, Inc. Announces Reverse Stock Split
8. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
10. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama ... Resolution Appropriations Act of 2015, which for the first ... through the Congressionally Directed Medical Research Programs (CDMRP) administered ... (HA), working in conjunction with its allies on Capitol ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... fighting to stay on budget as the first quarter of 2009 came to ... a field once thought immune to the troubles of the rest of the ... ... March 23, 2009 -- As the first quarter of 2009 came to a ...
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... its SCORPION(TM) multispecific therapeutic technology at the 100th ... Research (AACR) in Denver. The data presented demonstrated ... CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, ...
... Do winery tasting rooms really help generate sales for ... Innovation Centre almost half of winery tasting room visitors ... visit. , "This research proves that the tasting room ... in future sales," said Dr. Isabelle Lesschaeve, research director, ...
Cached Biology Technology:The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 3The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 4Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective 2
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the travel experience ... borders. Over the past decade, ePassports, biometric readers, and ... process through border control via eGates and Automated Passport ... seaports, and land borders across the globe. ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... previously thought to be disordered may in fact have an ... -- according to a study published by researchers at Fox ... Structure (Cell Press). The researchers published ... serves as a means of bringing together molecular signals between ...
... risen sharply in developed countries in the wake of the ... the condition. Foot problems are the most common cause of ... serious complications such as nerve damage and problems with the ... slow-healing wounds and foot ulcers which, if they get infected ...
... the principle of supply and demand at least at the ... proteins, are required at all times. That means most of their ... case in higher organisms. In the simplest case, a transcription factor ... that are regulated in a somewhat more complex manner, on the ...
Cached Biology News:'Disordered' amino acids may really be there to provide wiggle room for signaling protein 2'Disordered' amino acids may really be there to provide wiggle room for signaling protein 3Protective footwear for diabetics at a high-street price 2Protective footwear for diabetics at a high-street price 3The evolution of gene regulation 2The evolution of gene regulation 3